Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Although COVID-19 cases have fallen dramatically since a deadly wave in August, there is growing concern about the Omicron variant ... approved Moderna Inc's COVID-19 vaccine for its booster ...

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial.

Both Moderna and Pfizer-BioNTech vaccines can produce antibodies that protect against ... but they're not immune to the virus ...

Nigeria has joined the USAID-funded HIV-VISTA project as the only West African research site, aiming to develop a ...

The XEC COVID-19 variant is poised to become the dominant variant worldwide. Now is a good time to get an updated COVID ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna's Stéphane Bancel is stepping down from his role as chief commercial officer, a significant shift for the company as it approaches the rollout of several new vaccines. Source: Pixabay.

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Local health care providers and the Wyoming Department of Health are recommending that most people consider getting a ...